<DOC>
	<DOCNO>NCT01903187</DOCNO>
	<brief_summary>The purpose EnligHTN IV clinical investigation demonstrate safety effectiveness EnligHTN™ Renal Denervation System treatment subject drug-resistant uncontrolled hypertension .</brief_summary>
	<brief_title>EnligHTN IV Trial - Multicenter Sham-controlled RCT Renal Denervation Hypertension</brief_title>
	<detailed_description>The study enrollment terminate early sponsor . This related safety issue . At time enrollment halt , 2 treatment group randomization occur , sham group subject exit 1 month follow visit . Subject randomized treatment group follow three year post procedure .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<criteria>Subject ≥18 year age ≤ 80 year age time inform consent participation clinical investigation Subject must able willing provide write informed consent Subject must able willing comply require followup schedule Subject office Systolic Blood Pressure ≥ 160 mmHg base average 3 Blood Pressure read confirmatory visit ( except subject Diabetes Mellitus Type II must demonstrate office Systolic Blood Pressure ≥ 150 mmHg ) Subject daytime mean Systolic 24hour Ambulatory Blood Pressure value ≥ 140 mmHg measure two week screen period confirm confirmatory visit Subject take ≥ 3 antihypertensive medication concurrently full tolerate dos ( must include one diuretic ) subject take diuretic document intolerance least two ( 2 ) three ( 3 ) remain major class antihypertensive ( ACE / ARB , Calcium Channel Blockers , Beta blockers unable take 3 antihypertensive drug ) Intolerance define absolute contraindication antihypertensive medication accord approve labeling inability take antihypertensive medication prescribe due adverse drug effect include immune mediate response interaction medication . Subjects must stable antihypertensive medication regimen minimum 2 week prior complete initial screen visit medication regimen must remain unchanged 2 week screen period follow signing consent . Subject must assess confirmatory visit expect change least six ( 6 ) month Subject previous renal denervation attempt Subject know cause secondary hypertension sleep apnea Subjects significant renovascular abnormality renal artery stenosis &gt; 30 % , previous renal stenting angioplasty , renal artery occlusion , renal vein thrombosis , renal aneurysm renal atheroembolism Subject myocardial infarction , unstable angina pectoris , cerebrovascular accident &lt; 180 day prior enrollment Subject hemodynamically significant valvular heart disease determine Study Investigator Subject expect cardiovascular intervention within 180 day enrollment Subject blood clot abnormality thrombocytopenia , hemophilia , significant anemia Subject life expectancy &lt; 12 month , determine Study Investigator Subject participate another Clinical Investigation ( IND IDE ) Subject pregnant , nursing , childbearing potential use adequate contraceptive method Subject active systemic infection determine Study Investigator Subject main renal artery diameter ( ) &lt; 4 mm diameter &lt; 20 mm length multiple renal artery main renal artery supply &lt; 75 % kidney Subject eGFR &lt; 45 mL/min per 1.73 m2 use MDRD formula Subject evidence significant AAA define aneurysm size ≥5.0 cm width and/or involve renal artery , and/or require surgical percutaneous intervention within 6 month enrollment . Subject &gt; 1 inpatient hospitalization hypertensive crisis within 12 month Subject condition would interfere accurate interpretation study endpoints Any condition would prohibit interfere ability obtain accurate Blood Pressure measurement use CIP specific automatic Blood Pressure monitor Subject Systolic Blood Pressure value great 20mmHg apart six ( 6 ) measurement assess confirmatory visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>hypertension</keyword>
	<keyword>resistant hypertension</keyword>
	<keyword>renal denervation</keyword>
</DOC>